<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04267016</url>
  </required_header>
  <id_info>
    <org_study_id>TGRP01-US001</org_study_id>
    <nct_id>NCT04267016</nct_id>
  </id_info>
  <brief_title>Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care</brief_title>
  <official_title>A Clinical Pilot Study to Test the Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transplant Genomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Transplant Genomics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study in renal transplant recipients to evaluate the acceptability,
      feasibility, and clinical utility of TruGraf® testing in conjunction with standard clinical
      assessment. TruGraf is the first and only non-invasive test approved by Medicare to rule out
      silent rejection in stable kidney transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Utility of TruGraf Results</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Percent of total number of TruGraf results that the PI identified as having clinical utility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of TruGraf Results</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Percent of total number of TruGraf results that the PI identified as being correlated to other clinical results obtained through the standard of care.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of TruGraf Testing</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Percent of total number of eligible subjects for whom the PI was able to complete the entire TruGraf testing workflow</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Kidney Transplant Rejection</condition>
  <arm_group>
    <arm_group_label>All Subjects Enrolled</arm_group_label>
    <description>Renal transplant recipients who are undergoing routine management</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>TruGraf Testing - Peripheral blood gene expression profiling</intervention_name>
    <description>5 mL collection PAXgene blood sample</description>
    <arm_group_label>All Subjects Enrolled</arm_group_label>
    <other_name>Standard of care</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible renal transplant recipients who meet the inclusion/exclusion criteria will be
        part of this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient of a primary or subsequent deceased-donor or living donor kidney
             transplantation.

          -  Stable serum creatinine (current serum creatinine &lt;2.3 mg/dl, &lt;20% increase compared
             to the average of the previous 3 serum creatinine levels)

          -  Kidney transplant patients who &gt;90 days (+/- 2 weeks) post-transplant will be included
             in this study

        Exclusion Criteria:

          -  Need for combined organ transplantation with an extra-renal organ and/or islet cell
             transplant.

          -  Recipients of previous non-renal solid organ and/or islet cell transplantation.

          -  Infection with HIV.

          -  Infection with BK nephropathy.

          -  Patients that have nephrotic proteinuria (urine protein &gt;3 gm/day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John Holman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Transplant Genomics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Courtney Schieve</last_name>
    <phone>608-217-7978</phone>
    <email>courtney@transplantgenomics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Thompson, RN, MSN</last_name>
      <phone>919-681-6898</phone>
      <email>jennifer.thompson@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Debra Sudan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marsh CL, Kurian SM, Rice JC, Whisenant TC, David J, Rose S, Schieve C, Lee D, Case J, Barrick B, Peddi VR, Mannon RB, Knight R, Maluf D, Mandelbrot D, Patel A, Friedewald JJ, Abecassis MM, First MR. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function. Transplant Proc. 2019 Apr;51(3):722-728. doi: 10.1016/j.transproceed.2019.01.054. Epub 2019 Jan 26.</citation>
    <PMID>30979456</PMID>
  </reference>
  <reference>
    <citation>First MR, Peddi VR, Mannon R, Knight R, Marsh CL, Kurian SM, Rice JC, Maluf D, Mandelbrot D, Patel A, David J, Schieve C, Lee D, Lewis P, Friedewald JJ, Abecassis MM, Rose S. Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice. Transplant Proc. 2019 Apr;51(3):729-733. doi: 10.1016/j.transproceed.2018.10.024. Epub 2018 Dec 11.</citation>
    <PMID>30979457</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2020</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

